| [1] |
Walton KL, Makanji Y, Harrison CA. New insights into the mechanisms of activin action and inhibition [J]. Mol Cell Endocrinol, 2012, 359(1-2): 2-12.
|
| [2] |
Bloise E, Ciarmela P, Dela Cruz C, et al. Activin A in mammalian physiology [J]. Physiol Rev, 2019, 99(1): 739-780.
|
| [3] |
Maeshima A, Miya M, Mishima K, et al. Activin A: autocrine regulator of kidney development and repair [J]. Endocr J, 2008, 55(1): 1-9.
|
| [4] |
Maeshima A, Vaughn DA, Choi Y, et al. Activin A is an endogenous inhibitor of ureteric bud outgrowth from the Wolffian duct [J]. Dev Biol, 2006, 295(2): 473-485.
|
| [5] |
任玮，余宏川，王萍，等. miR-17-5p诱导小鼠肾足细胞系凋亡[J]. 基础医学与临床，2019, 39(7): 973-977.
|
| [6] |
张延蕊，武艺飞，王慧，等. 微小RNA-17-5p在小儿肾病综合征发病中的作用及其机制研究[J]. 中国当代儿科杂志，2020, 22(9): 958-963.
|
| [7] |
Takahashi S, Nakasatomi M, Takei Y, et al. Identification of urinary activin A as a novel biomarker reflecting the severity of acute kidney injury [J]. Sci Rep, 2018, 8(1): 5176.
|
| [8] |
Tsai YL, Chou RH, Lu YW, et al. Serum activin A levels and renal outcomes after coronary angiography [J]. Sci Rep, 2020, 10(1): 3365.
|
| [9] |
Jelkmann W. Activin receptor ligand traps in chronic kidney disease [J]. Curr Opin Nephrol Hypertens, 2018, 27(5): 351-357.
|
| [10] |
Spottiswoode N, Armitage AE, Williams AR, et al. Role of activins in hepcidin regulation during malaria [J]. Infect Immun, 2017, 85(12): e00191-17.
|
| [11] |
Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin [J]. Br J Haematol, 2014, 165(6): 870-882.
|
| [12] |
Mehta N, Krepinsky JC. The emerging role of activins in renal disease [J]. Curr Opin Nephrol Hypertens, 2020, 29(1): 136-144.
|
| [13] |
Hortells L, Sosa C, Guillén N, et al. Identifying early pathogenic events during vascular calcification in uremic rats [J]. Kidney Int, 2017, 92(6): 1384-1394.
|
| [14] |
Sugatani T. Systemic activation of activin A signaling causes chronic kidney disease-mineral bone disorder [J]. Int J Mol Sci, 2018, 19(9): 2490.
|
| [15] |
Sugatani T, Agapova OA, Fang Y, et al. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease [J]. Kidney Int, 2017, 91(1): 86-95.
|
| [16] |
Lima F, Mawad H, El-Husseini AA, et al. Serum bone markers in ROD patients across the spectrum of decreases in GFR: activin A increases before all other markers [J]. Clin Nephrol, 2019, 91(4): 222-230.
|
| [17] |
Nordholm A, Mace ML, Gravesen E, et al. Klotho and activin A in kidney injury: plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney [J]. Am J Physiol Renal Physiol, 2018, 314(5): F753-F762.
|
| [18] |
Nordholm A, Egstrand S, Gravesen E, et al. Circadian rhythm of activin A and related parameters of mineral metabolism in normal and uremic rats [J]. Pflugers Arch, 2019, 471(8): 1079-1094.
|
| [19] |
Wang Y, He G, Tang H, et al. Aspirin inhibits inflammation and scar formation in the injury tendon healing through regulating JNK/STAT-3 signalling pathway [J]. Cell Prolif, 2019, 52(4): e12650.
|
| [20] |
Zhang D, Gava AL, Van Krieken R, et al. The caveolin-1 regulated protein follistatin protects against diabetic kidney disease [J]. Kidney Int, 2019, 96(5): 1134-1149.
|
| [21] |
Bian X, Griffin TP, Zhu X, et al. Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy [J]. BMJ Open Diabetes Res Care, 2019, 7(1): e000720.
|
| [22] |
Kadiombo AT, Maeshima A, Kayakabe K, et al. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice [J]. Am J Physiol Renal Physiol, 2017, 312(2): F297-F304.
|
| [23] |
Takei Y, Takahashi S, Nakasatomi M, et al. Urinary activin A is a novel biomarker reflecting renal inflammation and tubular damage in ANCA-associated vasculitis [J]. PLoS One, 2019, 14(10): e0223703.
|
| [24] |
Iriuchishima H, Maeshima A, Takahashi S, et al. Activin A: a novel urinary biomarker of renal impairment in multiple myeloma [J]. Biosci Rep, 2019, 39(5): BSR20190206.
|
| [25] |
Koken E, Oyar EO, Uyanikgil Y, et al. Exogenous follistatin administration ameliorates cisplatin-induced acute kidney injury through anti-inflammation and anti-apoptosis effects [J]. Bratisl Lek Listy, 2020, 121(2): 143-150.
|
| [26] |
Yuan C, Ni L, Wu X. Activin A activation drives renal fibrosis through the STAT3 signaling pathway [J]. Int J Biochem Cell Biol, 2021, 134: 105950.
|
| [27] |
Cappellini MD, Porter J, Origa R, et al. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study [J]. Haematologica, 2019, 104(3): 477-484.
|
| [28] |
Komrokji RS. Activin receptor II ligand traps: new treatment paradigm for low-risk MDS [J]. Curr Hematol Malig Rep, 2019, 14(4): 346-351.
|
| [29] |
Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma [J]. Br J Haematol, 2014, 165(6): 814-823.
|
| [30] |
Agapova OA, Fang Y, Sugatani T, et al. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease [J]. Kidney Int, 2016, 89(6): 1231-1243.
|
| [31] |
Williams MJ, Sugatani T, Agapova OA, et al. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease [J]. Kidney Int, 2018, 93(1): 147-158.
|